Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients

Last updated: February 21, 2017
Sponsor: Novartis Pharmaceuticals
Overall Status: Completed

Phase

3

Condition

Kidney Transplantation

Treatment

N/A

Clinical Study ID

NCT00239863
CFTY720A0125E1
  • Ages 18-65
  • All Genders

Study Summary

This study will evaluate the safety and efficacy of FTY720 versus mycophenolate mofetil (MMF, Roche brand) combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Completion of core study

Exclusion Criteria

Other protocol-defined exclusion criteria may apply.

Study Design

Total Participants: 684
Study Start date:
May 01, 2004
Estimated Completion Date: